Nanomosaic
Nanomosaic empowers gene therapy innovators with rapid, comprehensive analytics through its Tessie™ platform and integrated assay suite. Recently granted FDA CBER Advanced Manufacturing Technology (AMT) designation, the platform analyzes viral vectors directly, with no purification required, delivering unique critical quality attributes for rapid screening to deep vector characterization across bioprocessing and manufacturing. By leveraging FDA AMT regulatory incentives, Nanomosaic adopters vastly derisk regulatory pathways, improve product quality, and accelerate manufacturing timelines for next-generation genetic medicines.
